(L to R) Michael Brown, Dan Galles, Stacy Feld, and Indu Subaiya chat on stage at Health 2.0 VentureConnect. (Photo by Jonah Comstock).
September 16, 2019
In the world of healthcare there are many stakeholders: hospitals and other providers, insurers and other payers, and, of course pharma and medical device companies. But one thing all these stakeholders have in common is that they’re increasingly moonlighting as investors.
At the kickoff of Health 2.0’s Venture Connect event today in Santa Clara, California, three of these strategic investors —...
June 4, 2019
Since it was first announced, fans and critics of the FDA’s Pre-Cert program for medical software developers have mused on the benefits and burdens that might come with participation in the experimental program.
What to expect from Pre-Cert
The question has only become more pertinent since the agency released its 1.0 Working Model in January and, just a couple weeks ago, began seeking new De Novo...
January 17, 2019
Earlier today, Johnson & Johnson announced plans for a multi-year research program it will be launching with Apple to explore the role Apple Watches could play in senior health monitoring.
Set to kickoff later this year, the pragmatic randomized controlled trial study will be conducted in the US and enroll adults aged 65 years or older, according to a statement. Specifically, the primary...
November 7, 2018
By and large, Q3 2018 was a slow and steady quarter for pharma moves in digital health, at least in terms of publicly disclosed operations. At events during the quarter, the likes of Johnson & Johnson, AstraZeneca, Novartis and Sanofi discussed digital therapeutics and expressed a healthy mixture of skepticism and enthusiasm for the space.
“These technologies have a tremendous opportunity to...
November 6, 2018
Apple’s healthcare patent update. A new Hong Kong and European trademark updates the classification of Apple’s AirPods to include health, fitness, exercise and wellness sensors (kudos to Patently Apple, which spotted the update). The updated classification also includes language concerning the transmission of biometric data, heart rate, body movement and burned calories.
Despite this and other...
Fitbit Medical Director John Moore. Photo by Christopher Huang.
October 19, 2018
Part of the value — and fun — of conferences like Connected Health Conference is seeing all the newest technologies debuting in the space, but sometimes tech evangelists need to be reminded of the limits of technology. That’s what speakers from both Fitbit and Johnson & Johnson shared this morning at the show.
“When I started in this space, there was a tremendous amount of excitement about...
(L to R) Moderator Scott Thiel, Pear Therapeutics' Dan Amor, Verily's Afia Asamoah, Tidepool's Howard Look, and Johnson & Johnson's Eduardo Sanchez (photo by Jonah Comstock)
October 19, 2018
Attendees to the Connected Health Conference in Boston this week got a sneak peek into the workings of the FDA's much-discussed Pre-Cert program. In a panel discussion at the event, representatives from Verily, Pear Therapeutics, Tidepool, and Johnson & Johnson candidly discussed their experiences so far with the program, describing an evolving process that is collaborative and rigorous.
September 26, 2018
As more and more partnerships between digital therapeutics and pharma companies begin to emerge, the two industries have started to size each other up. While this may foster an exchange of ideas, there is also the danger of concepts getting lost in translation between the two industries.
Yesterday DTx East in Boston pharma execs talked about the future, realities, and challenges of digital...
July 17, 2018
VitalConnect and physIQ are teaming up with the Haga Teaching Hospital in the Netherlands to conduct a study on how wearable biosensors and artificial intelligence can augment care for cancer patients undergoing treatment. Specifically, the study — which is funded by Johnson & Johnson subsidiary Janssen Pharmaceuticals — is looking to see how the technology can detect adverse events in cancer...
July 17, 2018
As Johnson & Johnson continues to move out of the diabetes business, the company has sold its Calibra product (marketed as OneTouch Via, but never launched) to CeQur, a 10-year-old company working on a similar insulin-delivery wearable. Terms of the deal were not disclosed, but CeQur has acquired an exclusive worldwide license for the technology.
“They’re divesting out of the diabetes market...